10% Off
Mes-D400 mg/4 m
Drug International Ltd.
৳171.00
Add to cart
Ifomes400 mg/4 ml
IV Injection
By
Best PriceTk /
1
Medicine overview
Indications of Ifomes 400 mg/4 ml
Ifomes 400 mg/4 ml is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
Theropeutic Class
Antidote preparations
Pharmacology
Ifomes 400 mg/4 ml is used to prevent urothelial toxicity associated with oxazaphosphorine, ifosfamide or cyclophosphamide.
Absorption
acrolein) of ifosfamide and cyclophosphamide.
Distribution
It is used as a mucolytic in the management of some respiratory tract conditions e.
Metabolism
It acts in the kidney; reacting with thiol groups of urotoxic metabolites (e.
Excretion
It acts by reducing the viscosity of pulmonary secretions; the drug's free sulfhydryl group is thought to reduce disulfide linkages of mucoproteins.
Dosage & Administration of Ifomes 400 mg/4 ml
Intravenous-Prophylaxis against urothelial toxicity
Dosage:Adult: Refer to individual and local protocol
Notes:Dose calculated according to cytotoxic dose. Normally given at a dose ≥cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall. Administered either by short (15-30 minutes) or continuous (24 hr) infusion
Child
Dosage:Refer to individual and local protocol
Notes:Has been used in children >4 mth
Oral-Prophylaxis against urothelial toxicity
Dosage:Adult: Refer to individual and local protocol
Notes:Dose calculated according to cytotoxic dose. Normally given at a dose ≥cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall
Child
Dosage:Refer to individual and local protocol
| Condition | Dosage | Notes |
|---|---|---|
| Intravenous-Prophylaxis against urothelial toxicity | Adult: Refer to individual and local protocol | Dose calculated according to cytotoxic dose. Normally given at a dose ≥cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall. Administered either by short (15-30 minutes) or continuous (24 hr) infusion |
| Child | Refer to individual and local protocol | Has been used in children >4 mth |
| Oral-Prophylaxis against urothelial toxicity | Adult: Refer to individual and local protocol | Dose calculated according to cytotoxic dose. Normally given at a dose ≥cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall |
| Child | Refer to individual and local protocol |
Dosage of Ifomes 400 mg/4 ml
Intravenous-Prophylaxis against urothelial toxicity
Dosage:Adult: Refer to individual and local protocol
Notes:Dose calculated according to cytotoxic dose. Normally given at a dose ≥cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall. Administered either by short (15-30 minutes) or continuous (24 hr) infusion
Child
Dosage:Refer to individual and local protocol
Notes:Has been used in children >4 mth
Oral-Prophylaxis against urothelial toxicity
Dosage:Adult: Refer to individual and local protocol
Notes:Dose calculated according to cytotoxic dose. Normally given at a dose ≥cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall
Child
Dosage:Refer to individual and local protocol
| Condition | Dosage | Notes |
|---|---|---|
| Intravenous-Prophylaxis against urothelial toxicity | Adult: Refer to individual and local protocol | Dose calculated according to cytotoxic dose. Normally given at a dose ≥cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall. Administered either by short (15-30 minutes) or continuous (24 hr) infusion |
| Child | Refer to individual and local protocol | Has been used in children >4 mth |
| Oral-Prophylaxis against urothelial toxicity | Adult: Refer to individual and local protocol | Dose calculated according to cytotoxic dose. Normally given at a dose ≥cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall |
| Child | Refer to individual and local protocol |
Contraindications
Hypersensitivity to thiol-containing compounds.
Side Effects of Ifomes 400 mg/4 ml
Nausea, vomiting, colic, diarrhoea, anorexia, dyspepsia, unpleasant taste, constipation; headache, malaise, fatigue, depression, irritability, somnolence, hyperaesthesia, dizziness, confusion; rash, pruritus, generalised urticaria, alopecia, inj site reactions, flushing; leucopenia, thrombocytopenia, anaemia, granulocytopenia, chest pain, oedema (peripheral, facial and periorbital), hypotension, tachycardia, hypertension, increased heart rate, ST-segment elevation; dyspnoea, coughing, pneumonia, tachypnea; fever; hypocalcaemia; increased sweating; back pain, limb pain, myalgia; increased hepatic enzyme concentrations; pharyngitis; ulceration of mucous membranes. In patients receiving oral and/or IV Ifomes 400 mg/4 ml and were specifically not treated with concurrent cytotoxic therapy: flatulence; rhinitis; rigors; back pain; rash; conjunctivitis; arthralgia. Inhalation: bronchospasm.
Pregnancy & Lactation
Pregnancy Category B. Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Precautions & Warnings
Protective effect applies only to the urinary tract; pregnancy, lactation. Patients with auto-immune disorders. IV formulation may contain benzyl alcohol as a preservative; avoid in neonates or infants. Instruct patients to seek medical attention if discolouration of urine occurs. During treatment, monitor urine for erythrocytes and haematuria. Maintain adequate hydration in all patients. Patients who vomit within 2 hr of oral dose should repeat dose or receive IV dose.
Storage Conditions
Should be stored at 15-30° C.
Reconstitution
Dilute in 50-1000 ml normal saline, 5% dextrose or lactated Ringer's.
Drug Classes
Antidote preparations
Mode Of Action
Ifomes 400 mg/4 ml is used to prevent urothelial toxicity associated with oxazaphosphorine, ifosfamide or cyclophosphamide. It acts in the kidney; reacting with thiol groups of urotoxic metabolites (e.g. acrolein) of ifosfamide and cyclophosphamide. It is used as a mucolytic in the management of some respiratory tract conditions e.g. cystic fibrosis where other mucolytics have failed. It acts by reducing the viscosity of pulmonary secretions; the drug's free sulfhydryl group is thought to reduce disulfide linkages of mucoproteins.
Pregnancy
Pregnancy Category B. Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Frequently Asked Questions
What is Ifomes 400 mg/4 ml used for?
Mesna is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
What is the dosage of Ifomes 400 mg/4 ml?
Intravenous-Prophylaxis against urothelial toxicity: Adult: Refer to individual and local protocol. Dose calculated according to cytotoxic dose. Normally given at a dose ≥cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall. Administered either by short (15-30 minutes) or continuous (…
What are the side effects of Ifomes 400 mg/4 ml?
Nausea, vomiting, colic, diarrhoea, anorexia, dyspepsia, unpleasant taste, constipation; headache, malaise, fatigue, depression, irritability, somnolence, hyperaesthesia, dizziness, confusion; rash, pruritus, generalised urticaria, alopecia, inj site reactions, flushing; leucopenia, thrombocytopenia, anaemia, granulocytopenia, chest pain, oedema (peripheral, facial and periorbital), hypotension, t…
Who should not take Ifomes 400 mg/4 ml?
Hypersensitivity to thiol-containing compounds.
What precautions should be taken with Ifomes 400 mg/4 ml?
Protective effect applies only to the urinary tract; pregnancy, lactation. Patients with auto-immune disorders. IV formulation may contain benzyl alcohol as a preservative; avoid in neonates or infants. Instruct patients to seek medical attention if discolouration of urine occurs. During treatment, monitor urine for erythrocytes and haematuria. Maintain adequate hydration in all patients. Patients…
Is Ifomes 400 mg/4 ml safe during pregnancy and breastfeeding?
Pregnancy Category B. Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.